Neuphoria Therapeutics Inc.
NEUP
$4.84
-$0.11-2.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.94M | -804.80K | -2.62M | -2.74M | -4.55M |
| Total Depreciation and Amortization | 166.10K | 165.70K | 331.50K | 331.50K | 165.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.25M | -2.60M | -1.01M | -999.40K | 655.90K |
| Change in Net Operating Assets | -328.20K | -1.20M | 727.40K | 727.40K | -212.30K |
| Cash from Operations | -3.36M | -4.43M | -2.57M | -2.68M | -3.95M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -71.30K | -69.70K | -- |
| Cash from Investing | -- | -- | -71.30K | -69.70K | -- |
| Total Debt Issued | -- | -- | -380.90K | -372.30K | -- |
| Total Debt Repaid | -- | -- | 28.30K | 27.60K | -- |
| Issuance of Common Stock | -- | 400.00 | 1.40M | 1.48M | 288.80K |
| Repurchase of Common Stock | -400.00 | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -111.20K | -227.70K | 2.81M | 2.80M | 5.34M |
| Cash from Financing | -111.60K | -227.30K | 3.86M | 3.94M | 5.63M |
| Foreign Exchange rate Adjustments | -276.70K | 138.40K | 161.30K | 158.50K | 343.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.75M | -4.52M | 1.38M | 1.36M | 2.02M |
